SIDE-EFFECTS OF STATINS
(SLCO1B1 GENE TEST)
Background
Statins are well established drugs for the treatment of hypercholesterolaemia and the prevention of atherosclerosis and related coronary heart disease. Treatment with statins leads to significant low-density lipoprotein cholesterol (LDL) lowering, reducing major coronary and vascular events. Although statins are generally well tolerated and safe; there is wide inter-individual variability in response to statin therapy, in terms of both lipid-lowering and adverse drug reactions.
SLCO1B1 Genotypes
SLCO1B1 V174A genotype | Frequency | Commentary |
VV | 70% | Normal SLCO1B1 activity. |
VA | 28% | Intermediate SLCO1B1 activity. Increased risk for statin-induced myopathy. |
AA | 2% | Low SLCO1B1 activity. Strongly increased risk for statin-induced myopathy. |
Indications for testing
Literatur:
-
New Genetic Tests
- Clopidogrel Resistance (CYP2C19)
- Statin Side-Effects (SLCO1B1)
- Morbus Wilson (ATP7B)